Imapextide
MBX Biosciences' once-weekly GLP-1 receptor antagonist for post-bariatric hypoglycemia. It cleared Phase 1, hit proof of concept in a 20-patient open-label Phase 2a in May 2026 — and was then shelved, with MBX stating it would not fund a Phase 2b. Its competitor avexitide has since posted positive Phase 3 data.
Imapextide is a weekly injection designed to block the GLP-1 receptor and stop the dangerous blood-sugar crashes some people get after gastric bypass surgery. It worked well enough in a small open-label study for its maker to call it proof of concept — and in the same announcement MBX said it would not pay for the next trial. A rival drug, avexitide, has since succeeded in a full Phase 3.
What is Imapextide?
Imapextide (development code MBX 1416) is a sustained-action, selective, reversible glucagon-like peptide-1 receptor antagonist developed by MBX Biosciences for post-bariatric hypoglycemia (PBH). Where most of this directory's GLP-1 entries are agonists, imapextide does the opposite: it blocks the receptor, to prevent the inappropriate insulin surges that cause reactive hypoglycemia after Roux-en-Y gastric bypass. It was engineered for once-weekly subcutaneous dosing using MBX's prodrug peptide platform. Its status is the most important thing about it, and it is not what the development-stage label suggests. The Phase 1 study in 69 healthy volunteers published in the Journal of Clinical Endocrinology & Metabolism in May 2026 (first author Fabbrini, not Davenport as some secondary sources state) supported weekly dosing on pharmacokinetic grounds — mean half-life around 90 hours. The Phase 2a STEADI trial in PBH patients (NCT07029412) completed in May 2026 with 20 participants enrolled. On 11 May 2026, MBX announced the results and the programme's suspension in the same release: once-weekly imapextide 'achieved proof of concept (POC) in PBH,' and chief executive Kent Hawryluk stated that 'we will not be committing further investment toward a Phase 2b trial of imapextide in PBH.' As of late October 2026, imapextide does not appear anywhere on MBX's published pipeline, which lists canvuparatide (MBX 2109) in Phase 3 for hypoparathyroidism and three obesity programmes — MBX 4291, MBX 5765 and MBX 6180. The company's quarterly filings mention imapextide only in liquidity notes alongside preclinical assets. No partner or licensee has been announced. This page is retained because the data are real and the mechanism is validated — and because the compound is a clean case study in a drug working and being shelved anyway.
What Imapextide Is Investigated For
Imapextide's only tested indication is post-bariatric hypoglycemia, and the data that exist are genuinely positive — they are simply too thin, and now too orphaned, to support a clinical recommendation. In the Phase 2a STEADI trial MBX reported average increases from baseline in glucose nadir of 17%, 28% and 34% at 45 mg, 100 mg and 200 mg respectively, with average decreases in insulin peak of 11%, 33% and 45%. That is a clean dose-response on both the glucose and insulin sides of the pathophysiology. But STEADI was open-label, single-arm, unmasked and unrandomised, with 20 participants and three mixed-meal tolerance tests; no results have been posted to ClinicalTrials.gov and no peer-reviewed publication exists. The competitive context explains the decision better than the data do. Imapextide's entire differentiation was dosing convenience against avexitide — and that advantage is much smaller than this page previously claimed. Avexitide's Phase 2b used 45 mg twice daily and 90 mg **once daily**, and its Phase 3 LUCIDITY trial used 90 mg once daily. The real contrast is weekly versus once-daily, not weekly versus two or three times daily. Meanwhile avexitide delivered: the Phase 2b reduced diurnal Level 2 hypoglycemia events by 47.7% and 59.0% and Level 3 events by 67.5% and 66.1%, and Amylyx reported in August 2026 that the Phase 3 met its FDA-agreed primary endpoint with a 55% reduction in combined Level 2 and Level 3 events, with an NDA planned by the end of 2026. Avexitide holds Breakthrough Therapy and Orphan Drug designations and now has an expanded access protocol open. For a reader with PBH, the practical answer is that imapextide is not obtainable and not coming, while avexitide is in late-stage regulatory play with an expanded access route. Congenital hyperinsulinism was never tested with imapextide; extrapolation from avexitide's work in that setting was always speculative and is now moot.
History & Discovery
Imapextide came out of MBX Biosciences' Precision Endocrine Peptide platform, which builds prodrug peptides designed for extended dosing intervals — the same approach behind canvuparatide for hypoparathyroidism and the company's obesity candidates. The therapeutic idea was not novel: GLP-1 receptor antagonism for post-bariatric hypoglycemia traces back to exendin-(9-39) and was carried into clinical development by Eiger BioPharmaceuticals as avexitide, later acquired by Amylyx. MBX's contribution was pharmacokinetic rather than mechanistic — take a validated target and give it a weekly dosing interval. The Phase 1 programme ran from September 2023 to December 2024 (NCT06036784), enrolling 69 healthy volunteers across single-dose, multiple-dose and drug-interaction parts, and was published in May 2026. The Phase 2a STEADI trial (NCT07029412) opened in August 2025 across sites in Colorado, North Carolina, Tennessee and Texas, enrolling 20 participants with post-bariatric hypoglycemia for an open-label, single-arm evaluation built around mixed-meal tolerance tests at baseline and after each of two single subcutaneous doses. Primary completion was recorded on 18 April 2026. The programme ended three weeks later. On 11 May 2026 MBX reported the STEADI results and the decision together: proof of concept achieved, no Phase 2b funded. The numbers were not the problem — glucose nadir rose and insulin peak fell in a clean dose-dependent pattern. The problem was the race. Avexitide had by then completed a Phase 2b showing roughly 48% to 59% reductions in diurnal Level 2 hypoglycemia events, held Breakthrough Therapy and Orphan Drug designations, and had a Phase 3 reading out within months. When LUCIDITY did read out in August 2026, it met its FDA-agreed primary endpoint with a 55% reduction in combined Level 2 and Level 3 events, and Amylyx stated it planned to file a New Drug Application by the end of 2026, with possible launch in 2027. Imapextide's differentiator had also narrowed on inspection. It was built to beat a dosing burden that turned out to be once daily rather than several times daily, in a rare indication where the first approved product would take most of the market. By October 2026 the compound had been removed from MBX's pipeline page entirely, appearing in filings only in liquidity notes grouped with preclinical assets. No partner has been named. The scientific record is a positive Phase 1, a positive small Phase 2a that was never published, and a sponsor that walked away from both.
How It Works
After gastric bypass, food reaches the lower intestine much faster than it used to. That triggers an oversized release of the hormone GLP-1, which tells the pancreas to release far more insulin than the meal warrants — and blood sugar crashes one to three hours after eating. Imapextide blocks the receptor GLP-1 acts on, so the insulin response stays proportionate. Because it was engineered to last, one injection was meant to cover a full week of meals.
Post-bariatric hypoglycemia follows from anatomy. After Roux-en-Y gastric bypass, nutrients arrive rapidly at the distal small bowel, driving exaggerated postprandial secretion of GLP-1 from intestinal L-cells. GLP-1 amplifies glucose-stimulated insulin secretion at the pancreatic beta cell, so the result is hyperinsulinemia disproportionate to the glycemic load and reactive hypoglycemia typically 1 to 3 hours after eating. The condition is more common than its profile suggests — reported as complicating up to 30% of Roux-en-Y procedures and up to 10% of sleeve gastrectomies — and similar presentations follow total gastrectomy, esophagectomy and Nissen fundoplication, all sharing postprandial GLP-1 hypersecretion. Imapextide is a selective, reversible competitive antagonist at the GLP-1 receptor: it occupies the receptor without activating it, blocking the amplification step rather than the hormone's release. MBX built sustained action using its prodrug peptide platform; the resulting pharmacokinetics — dose-proportional exposure, median time to peak of 24 to 48 hours, mean half-life around 90 hours — are what supported a weekly interval covering the meal-induced GLP-1 surges across the whole dosing period. Two mechanistic caveats are worth holding onto. First, the Phase 1 pharmacodynamic readout was an increase in circulating GLP-1 at early time points, with variable effects on other glycemic parameters. Rising endogenous GLP-1 is the expected consequence of blocking its receptor and removing feedback inhibition, so it is reasonable evidence of target engagement — but it is an indirect marker, not a measurement of receptor occupancy, and the authors were careful about how they framed it. Second, the GLP-1 hypersecretion story may be less complete than it looks. A 2026 randomised crossover study in PBH found that acarbose attenuated the beta-cell response while total GLP-1 area under the curve was unchanged, and separate 2026 work found gastric emptying about three times faster in PBH than controls, with a GLP-1 receptor agonist slowing emptying yet failing to prevent hypoglycemia. Rate of nutrient delivery, incretin amplification and beta-cell sensitivity are entangled, and blocking one node may not be sufficient — which also makes imapextide's own slight acceleration of gastric emptying a question worth having asked.
Evidence Snapshot
Human Clinical Evidence
Phase 1 complete and published (J Clin Endocrinol Metab 2026, 69 healthy volunteers). Phase 2a STEADI (NCT07029412) complete with 20 participants, open-label, single-arm, no masking or randomisation, three mixed-meal tolerance tests; MBX reported dose-dependent increases in glucose nadir (17%, 28%, 34%) and decreases in insulin peak (11%, 33%, 45%) at 45, 100 and 200 mg. No results posted to ClinicalTrials.gov, no peer-reviewed Phase 2a publication, and development halted. Nothing beyond Phase 2a will be generated.
Animal / Preclinical
Not separately published. GLP-1 receptor antagonism for post-bariatric hypoglycemia was already clinically validated by exendin-(9-39) and avexitide before imapextide entered humans, so the preclinical burden was mainly on the sustained-action chemistry rather than the mechanism.
Mechanistic Rationale
Strong, and independent of imapextide's own fate. GLP-1 receptor antagonism for PBH has now been validated through avexitide's positive Phase 2b and Phase 3 results. The open question is not whether the mechanism works but whether the GLP-1 axis is the whole story, given that gastric emptying rate and beta-cell sensitivity contribute independently.
Research Gaps & Open Questions
What the current literature has not yet settled about Imapextide:
- 01Everything beyond Phase 2a, permanently. MBX will not fund a Phase 2b, no partner has been announced, and the compound has been removed from the company's pipeline. These gaps are now unlikely ever to close.
- 02Publication of the Phase 2a data. No results have been posted to ClinicalTrials.gov and no peer-reviewed paper exists; the glucose-nadir and insulin-peak figures are available only from a company press release, which is a materially weaker evidence standard than the rest of this page's citations.
- 03Repeated weekly dosing in PBH patients. The Phase 2a gave at most two single doses roughly two weeks apart, yet the intended use was indefinite chronic therapy. Steady-state efficacy, tolerability and durability in the target population are entirely uncharacterised.
- 04The gastric-emptying question. Imapextide slightly accelerated gastric emptying in Phase 1, while rapid gastric emptying is roughly three times faster in PBH than in controls and contributes independently to the hypoglycemia. Whether this partially offsets the drug's benefit was never tested.
- 05Head-to-head against avexitide. Never performed, and now impossible. Whether weekly dosing produces equivalent symptomatic control to once-daily dosing in PBH is unanswerable from the existing data.
- 06Congenital hyperinsulinism. Extrapolated from avexitide's work in that setting but never tested with imapextide at any stage.
- 07Enrollment discrepancy. ClinicalTrials.gov records 20 participants enrolled in STEADI while MBX's own investor materials describe 14 participants across 20 baseline mixed-meal tolerance tests. The discrepancy is unresolved and matters for interpreting per-dose subgroup sizes, which were small.
Forms & Administration
Once-weekly subcutaneous injection in trials, at doses of 45, 100 and 200 mg in the Phase 2a and 10-200 mg in Phase 1. Not commercially available and no longer in development — there is no trial to enrol in and no expanded access programme for imapextide. Patients seeking a GLP-1 receptor antagonist for post-bariatric hypoglycemia should ask their bariatric medicine specialist about avexitide, which has an open expanded access protocol.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
Phase 1 used single subcutaneous doses of 10-200 mg and multiple doses of 10-30 mg weekly for four weeks. The Phase 2a used single subcutaneous doses of 45, 100 and 200 mg, with the dose-response running across all three. No Phase 2b dose was ever selected because no Phase 2b was run.
Frequency
Once weekly subcutaneous injection — the design goal, supported by a mean half-life of approximately 90 hours and dose-proportional exposure.
Timing Considerations
No specific timing requirements: can be administered at any time of day, with or without food, and is not tied to exercise timing. Consistency matters more than the specific clock — dose at roughly the same time each day (or same day each week, for weekly protocols) to keep exposure steady.
Cycle Length
Would have been chronic indefinite therapy, since post-bariatric hypoglycemia persists as long as the altered anatomy does. No cycling concept applies. Note that chronic weekly dosing in PBH patients was never studied — the Phase 2a gave at most two single doses about two weeks apart.
Protocol Notes
Imapextide is not obtainable. There is no open trial, no expanded access programme, and no commercial supply, and no route exists for a patient to access it. Anyone offered 'imapextide' outside a clinical trial is being sold something that is not imapextide. What is actionable for post-bariatric hypoglycemia has changed materially in 2026 and is worth stating plainly, because this is a condition where people search for options. Non-pharmacological management — low-glycemic-load meals, carbohydrate restriction, smaller and more frequent eating, continuous glucose monitoring — remains the foundation of care. Acarbose and somatostatin analogues are the established pharmacological adjuncts, with the caveat that a 2026 randomised crossover found acarbose attenuates the beta-cell response without changing total GLP-1 exposure, and that adding canagliflozin to it added nothing. Avexitide is the agent nearest approval, and Amylyx has an expanded access protocol open for PBH, which is a concrete and currently available route outside a trial. Mizagliflozin, an SGLT1 inhibitor, has single-dose trial data showing a raised glucose nadir and a 53% reduction in peak insulin. CGM-guided forecasting algorithms have also been tested in a randomised trial. All of this belongs to a bariatric medicine specialist. Post-bariatric hypoglycemia is frequently misdiagnosed, its fasting presentations are under-recognised, and the treatments that work operate on a narrow margin between hypoglycemia and hyperglycemia.
Imapextide is investigational, its development has been halted by its sponsor, and it is not approved or available in any jurisdiction. Post-bariatric hypoglycemia requires bariatric medicine specialty care.
Timeline of Effects
Onset
In the Phase 2a, pharmacodynamic effect was assessed at the time of maximum concentration after a single subcutaneous dose, consistent with a median time to peak of 24 to 48 hours from Phase 1. Effects on glucose nadir and insulin peak were measured during mixed-meal tolerance tests roughly 48 hours after dosing. No data exist on how quickly symptomatic benefit would appear in day-to-day life.
Peak Effect
Dose-dependent across the range tested: glucose nadir rose 17%, 28% and 34% and insulin peak fell 11%, 33% and 45% at 45, 100 and 200 mg respectively. The dose-response had not plateaued at 200 mg, so the ceiling was never established.
After Discontinuation
Pharmacological effect would dissipate over roughly two to three weeks given the ~90-hour half-life, and symptomatic hypoglycemia would return, since nothing about the underlying post-surgical anatomy or incretin physiology is altered by the drug. This was never formally studied; no washout data were reported.
Monitoring & Measurement
Bloodwork & Labs
- •Continuous glucose monitoring — the primary endpoint instrument in modern PBH trials, capturing Level 2 (<54 mg/dL) and Level 3 (severe) events
- •Mixed-meal tolerance test with paired glucose and insulin sampling — how glucose nadir and insulin peak were measured in STEADI
- •Self-monitored blood glucose, as a complement to CGM
- •Plasma insulin, C-peptide and proinsulin during symptomatic episodes, to confirm hyperinsulinemic hypoglycemia
- •HbA1c — of limited value here, since postprandial crashes and normal averages coexist
Functional & Performance Tests
- •Gastric emptying study — relevant because emptying is roughly three times faster in PBH and contributes independently to the hypoglycemia
- •Symptom and hypoglycemia-event diaries, including neuroglycopenic episodes
- •Validated quality-of-life instruments used in PBH trials, such as HFS-II and EQ-5D-5L
When to Test
Continuous glucose monitoring over a baseline period before any intervention, then repeated on treatment — modern PBH trials use 14-day run-in periods. Mixed-meal tolerance testing is the standard provocation when the diagnosis is in question. Fasting glucose deserves attention too, since fasting hypoglycemia in PBH is increasingly recognised and easily missed by purely postprandial monitoring.
Interpretation & Notes
Post-bariatric hypoglycemia is diagnosed and followed with instruments the patient can carry, which is unusual among the conditions in this directory and makes the monitoring section genuinely actionable. CGM is the central tool: it establishes event frequency and severity, it is the endpoint regulators have accepted, and it reveals the nocturnal and fasting events that symptom diaries miss. A CGM-guided forecasting algorithm has itself been tested in a randomised trial as a mitigation strategy. The two thresholds that matter are Level 2 (glucose below 54 mg/dL) and Level 3 (severe, requiring assistance). Both avexitide trials were built on these, so they are the numbers to use when comparing any PBH treatment. None of this is relevant to imapextide specifically, since the drug cannot be obtained. It is included because readers arriving at this page are usually looking for post-bariatric hypoglycemia answers rather than for this particular molecule, and knowing what their specialist should be measuring is more useful to them than the fate of a shelved asset.
Common Questions
Is imapextide still in development?
No. MBX announced on 11 May 2026 that the Phase 2a STEADI trial achieved proof of concept in post-bariatric hypoglycemia and, in the same release, that it 'will not be committing further investment toward a Phase 2b trial of imapextide in PBH.' The compound has since disappeared from MBX's published pipeline, which now shows canvuparatide and three obesity programmes. No partner or out-licensing deal has been announced.
If it worked, why was it dropped?
Capital allocation, by the company's own account — the CEO framed it as 'prioritizing our resources and capital allocation represents the strongest opportunity to deliver long-term value.' The commercial logic is not hard to reconstruct: imapextide's differentiation was dosing convenience over avexitide, avexitide turned out to be once-daily rather than multiple-daily, and avexitide reached positive Phase 3 with Breakthrough Therapy designation while imapextide was still in a 20-patient open-label Phase 2a. Running a Phase 2b and Phase 3 to arrive second in a rare-disease indication is a hard case to fund.
How is imapextide different from avexitide?
Both are GLP-1 receptor antagonists for post-bariatric hypoglycemia, and both derive conceptually from exendin-(9-39). Imapextide was engineered for once-weekly subcutaneous dosing, with a mean half-life of about 90 hours. Avexitide is dosed 90 mg subcutaneously once daily in its Phase 2b and Phase 3 trials. So the dosing gap is weekly versus daily — a genuine convenience advantage, but considerably narrower than the two-or-three-times-daily comparison often quoted, including by an earlier version of this page.
What did the Phase 1 study actually show?
Pharmacokinetics good enough to justify weekly dosing, and pharmacodynamics that were more equivocal than usually reported. Across 69 healthy volunteers, exposure was dose-proportional with a median time to peak of 24 to 48 hours and a mean half-life around 90 hours. On the pharmacodynamic side, the authors state imapextide 'increased GLP-1 concentrations at early time points, while effects on other glycemic parameters were variable.' Rising endogenous GLP-1 is the expected feedback signature of receptor blockade, not a direct measurement of it — so describing Phase 1 as having demonstrated durable receptor blockade, as this page previously did, overstates what was shown.
Were there safety concerns?
Nothing that drove the decision. Treatment-emergent adverse events ranged from 33.3% to 50.0% in single-dose cohorts and 33.3% to 100% in multiple-dose cohorts, dominated by injection-site erythema and swelling. Drug-drug interaction testing found minimal, non-clinically-relevant interaction with rosuvastatin. One finding deserves attention given the indication: imapextide slightly accelerated gastric emptying. Rapid gastric emptying is itself a driver of post-bariatric hypoglycemia, so a PBH drug that accelerates it further raises a mechanistic question that the small Phase 2a was not designed to answer.
What should someone with post-bariatric hypoglycemia do now?
Work with a bariatric medicine specialist. Dietary modification remains the foundation, with acarbose and somatostatin analogues as established pharmacological adjuncts — though a 2026 crossover study found acarbose attenuates the beta-cell response while adding canagliflozin contributed nothing further. Avexitide is the agent closest to approval, and Amylyx has opened an expanded access protocol for PBH, which is a concrete route outside a trial. Other mechanisms are also now in play: a single-dose trial of the SGLT1 inhibitor mizagliflozin raised glucose nadir and cut peak insulin by 53%.
Could imapextide come back?
Possible but unsupported by anything public. MBX has not announced a partner, a licensee, or any intent to restart, and the compound is absent from the pipeline page. The asset itself is not dead in a scientific sense — it has human proof-of-concept data and a validated mechanism — which is exactly the profile that sometimes gets picked up by another developer. Until that is announced, treat it as shelved.
Who Imapextide Is NOT For
- •Not available for use in any setting — development has been halted and no trial or expanded access route exists.
- •Concurrent GLP-1 receptor agonist therapy — directly opposing mechanisms at the same receptor.
- •DPP-4 inhibitors — these raise endogenous GLP-1, the signal a GLP-1 antagonist is intended to block.
- •Type 1 or type 2 diabetes requiring intact incretin signalling for glycemic control.
- •Use outside confirmed post-bariatric hypoglycemia — it was never studied in any other population.
- •Pregnancy and breastfeeding — no data in either setting.
- •Known hypersensitivity.
Drug & Supplement Interactions
Formal drug-drug interaction work was done in Phase 1 and is more informative than the mechanistic speculation that usually fills this section. MBX evaluated OATP1B1 and OATP1B3 transporter inhibition using coproporphyrin-I and rosuvastatin, and gastric emptying using acetaminophen. The result was that 'minimal nonclinically relevant DDIs occurred with rosuvastatin,' meaning imapextide is unlikely to meaningfully interfere with statins and other OATP1B substrates. The same testing found that imapextide slightly accelerated gastric emptying, which is pharmacodynamically relevant in a population whose hypoglycemia is partly driven by rapid nutrient delivery. The mechanistic contraindications are straightforward. GLP-1 receptor agonists — semaglutide, tirzepatide, liraglutide — act at the receptor imapextide blocks, so the combination is self-defeating. DPP-4 inhibitors raise endogenous GLP-1 and would work against the drug's purpose. Worth noting that the relationship between incretin drugs and post-bariatric hypoglycemia is not purely antagonistic in practice: there are published case reports of tirzepatide being used for PBH, and a GLP-1 receptor agonist has been shown to slow the pathologically rapid gastric emptying of PBH even while failing to prevent hypoglycemia. The physiology is more tangled than a simple agonist-versus-antagonist framing allows. Combination with the established PBH adjuncts — acarbose, somatostatin analogues, diazoxide — would have been plausible and was never studied with imapextide.
Safety Profile
Common Side Effects
Cautions
- • Development halted — not obtainable through any trial or expanded access route
- • Never studied outside confirmed post-bariatric hypoglycemia
- • Mechanistically opposed to GLP-1 receptor agonist therapy; the two should not be combined
- • Phase 2a was open-label, single-arm and unmasked, with no control group
What We Don't Know
The safety database stops at 69 healthy volunteers plus 20 PBH patients given at most two single doses roughly two weeks apart, and no results have been posted to ClinicalTrials.gov or published for the Phase 2a. Nothing is known about repeated weekly dosing in PBH patients over months, which is how the drug would actually have been used — PBH is a chronic condition requiring indefinite therapy. The gastric-emptying acceleration seen in Phase 1 is the most interesting open question: emptying rate is roughly three times faster in PBH than in controls, and a drug that speeds it further could in principle work against itself. No study has characterised that interaction, and now none will.
Legal Status
United States
Investigational and no longer in active development. Not FDA-approved, with no new drug application on file and no record in Drugs@FDA. MBX Biosciences stated on 11 May 2026 that it would not fund a Phase 2b in post-bariatric hypoglycemia, and the compound no longer appears on the company's published pipeline. No orphan drug designation for imapextide could be verified — MBX's canvuparatide holds one, and avexitide holds Breakthrough Therapy and Orphan Drug designations, but no public record of an imapextide designation was found, so this page makes no such claim.
International
Investigational across all major regulators, with no marketing authorisation application anywhere. Both registered trials were conducted in the United States. Development having been halted by the sponsor, no international regulatory pathway is open.
Sports & Competition
Not named anywhere on the WADA 2027 Prohibited List, and GLP-1 receptor antagonism is not a performance-enhancing mechanism — the pharmacology is aimed at preventing hypoglycemia, not at body composition or endurance. As an unapproved investigational substance it would nonetheless fall under S0, which prohibits any pharmacological substance not addressed in a later section and with no current approval by any governmental regulatory health authority for human therapeutic use. The practical point is moot given that the compound cannot be obtained.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
Imapextide is a promising Phase 2-stage competitor to avexitide.
Reality
That was true until 11 May 2026. In that announcement MBX reported proof of concept from the Phase 2a and simultaneously stated it would not commit further investment toward a Phase 2b. The compound has since been removed from MBX's published pipeline. Avexitide, meanwhile, met its Phase 3 primary endpoint in August 2026 with an NDA planned by year end. Describing imapextide as an active competitor is a year out of date.
Myth
Imapextide was dropped because it did not work.
Reality
The data were positive. Glucose nadir rose 17%, 28% and 34% and insulin peak fell 11%, 33% and 45% across ascending doses, and MBX itself called it proof of concept. The company framed the decision as capital allocation, prioritising canvuparatide and its obesity programmes. This is a drug that worked in a small study and was shelved on commercial grounds — a distinction worth preserving, because 'failed' and 'deprioritised' are different signals about a mechanism.
Myth
Once-weekly imapextide would have been far more convenient than avexitide's two-or-three-times-daily regimen.
Reality
Avexitide is not dosed two or three times daily. Its Phase 2b tested 45 mg twice daily and 90 mg once daily, and the Phase 3 used 90 mg once daily. The real comparison is weekly versus once-daily injection — still an advantage, but a far narrower one than the version repeated across secondary sources and in an earlier draft of this page, and narrow enough to matter when weighing a full development programme against an entrenched first mover.
Myth
Phase 1 demonstrated durable GLP-1 receptor blockade across the week.
Reality
Phase 1 demonstrated pharmacokinetics consistent with weekly dosing — a mean half-life around 90 hours — plus increased circulating GLP-1 at early time points, with 'effects on other glycemic parameters' that the authors describe as variable. Rising endogenous GLP-1 is the expected feedback signature of receptor blockade and reasonable evidence of target engagement, but it is not a direct measurement of sustained receptor occupancy, and the published conclusion is correspondingly measured.
Myth
Imapextide and avexitide are essentially the same molecule.
Reality
They share a target and a therapeutic concept, not a structure. Avexitide descends from exendin-(9-39), the naturally derived GLP-1 receptor antagonist fragment. Imapextide is a distinct sustained-action construct built on MBX's prodrug peptide platform specifically to achieve a weekly interval. Similar pharmacology, different chemistry — and only one of them has Phase 3 data.
Published Research
16 studiesAcute Effects of Acarbose and Canagliflozin, Alone and in Combination, on Postprandial GLP-1 and Glycaemic Responses in Post-Bariatric Hypoglycaemia: A Randomised Crossover Study.
Yang et al. (Diabetes Obes Metab 2026) — directly tests the acarbose adjunct that remains standard PBH management, and complicates the tidy GLP-1 story. Acarbose attenuated the beta-cell response while total GLP-1 area under the curve was unchanged, and adding canagliflozin contributed nothing further. Useful counterweight to any account that treats exaggerated GLP-1 release as the sole lever in this condition.
Beyond Postprandial Symptoms: Fasting Hypoglycemia in Post-Bariatric Hypoglycemia.
Rapid gastric emptying rate in postbariatric hypoglycemia and effect of glucagon-like peptide-1 receptor agonist on postprandial hypoglycemia.
Turk et al. (J Clin Endocrinol Metab 2026) — the study that turns imapextide's incidental Phase 1 finding into a real question. Gastric emptying is roughly three times faster in post-bariatric hypoglycemia than in controls, and a GLP-1 receptor agonist slowed emptying but did not prevent hypoglycemia. Imapextide was measured to slightly accelerate gastric emptying, which in this indication is the wrong direction — a mechanistic interaction no trial was designed to test.
Efficacy and safety of avexitide for treatment of hypoglycemia following bariatric and other upper gastrointestinal surgeries: a phase 2b study.
Craig et al. (Metabolism 2026) — the competitor data that reframe imapextide's whole rationale. Crossover study of avexitide 45 mg twice daily and 90 mg once daily against baseline: diurnal Level 2 hypoglycemia events by CGM fell 47.7% and 59.0% (both p≤0.0001), Level 3 events 67.5% and 66.1%, with quality-of-life improvement on 90 mg once daily. The once-daily arm is the key fact — imapextide's weekly dosing was differentiating against a daily comparator, not the two-or-three-times-daily regimen often quoted.
Post-bariatric hypoglycaemia: an under-recognized complication of weight loss surgery - a case series.
Tirzepatide for treatment of postbariatric hypoglycemia after Roux-en-Y gastric bypass: a report of 3 cases.
A single dose trial of mizagliflozin for the treatment of postbariatric hypoglycemia.
Lawler et al. (J Endocr Soc 2026) — evidence that the PBH field has moved beyond a two-horse GLP-1-antagonist race. The SGLT1 inhibitor mizagliflozin raised glucose nadir and cut peak insulin by 53% in a single-dose crossover, acting on intestinal glucose absorption rather than incretin signalling. A third mechanism competing for a small indication is part of the commercial context for MBX's decision.
Recognizing and preventing post-bariatric hypoglycemia: a clinical challenge!
Prevalence of post-bariatric hypoglycemia in the United States.
Clinical Efficacy Evaluation of a Continuous Glucose Monitoring-Guided Forecasting Algorithm to Mitigate Postbariatric Hypoglycemia: A Randomized Controlled Trial.
Sustained Action of Imapextide, A Glucagon-Like Peptide-1 Receptor Antagonist, in Healthy Volunteers.
Fabbrini et al. (J Clin Endocrinol Metab 2026) — the only peer-reviewed publication on imapextide that exists. Three-part Phase 1 in 69 healthy volunteers: 32 single-ascending-dose (10-200 mg), 23 multiple-ascending-dose (10-30 mg weekly × 4), 14 drug-drug interaction. Dose-proportional exposure, median tmax 24-48 h, mean half-life ~90 h. Most common events were injection-site erythema and swelling. Two findings the page leans on: 'imapextide increased GLP-1 concentrations at early time points, while effects on other glycemic parameters were variable,' and 'imapextide slightly accelerated gastric emptying.' Note the first author is Fabbrini — secondary sources attributing this paper to Davenport are wrong.
MBX Biosciences Reports First Quarter 2026 Financial Results and Business Highlights (Form 8-K, Exhibit 99.1)
MBX Biosciences 8-K, filed 11 May 2026 — the primary source for both the Phase 2a result and the programme's suspension, announced together. Reports that 'once-weekly imapextide achieved proof of concept (POC) in PBH,' with average increases from baseline in glucose nadir of 17% (45 mg), 28% (100 mg) and 34% (200 mg) and average decreases in insulin peak of 11%, 33% and 45%. In the same release CEO Kent Hawryluk states 'we will not be committing further investment toward a Phase 2b trial of imapextide in PBH,' framed as 'prioritizing our resources and capital allocation.'
ClinicalTrials.gov: Study to Evaluate Efficacy and Dose Response of Imapextide (STEADI), NCT07029412
ClinicalTrials.gov: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MBX 1416 in Healthy Subjects, NCT06036784
ClinicalTrials.gov: Avexitide for Treatment of Post-Bariatric Hypoglycemia (LUCIDITY), NCT06747468
ClinicalTrials.gov: Expanded Access Protocol to Provide Avexitide in Patients With Post-Bariatric Hypoglycemia, NCT07582874
Quick Facts
- Class
- Sustained-Action GLP-1 Receptor Antagonist
- Tier
- D
- Evidence
- Preliminary
- Safety
- Limited Data
- Updated
- Oct 2026
- Citations
- 16PubMed
Also known as
Tags
Related Goals
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.